All articles by Joshua Silverwood

Joshua Silverwood

Bayer’s stock drops to new 18-year low after asundexian trial termination

As per recommendations, Bayer will continue to investigate asundexian in a different Phase III trial with stroke patients.

UK unveils £520m for life sciences as part of Autumn Statement 2023

The UK’s Autumn 2023 Statement takes a special interest in revitalising parts of the life sciences scene.

UK launches medicines scheme with £400m earmarked for clinical trials

The new scheme will launch in 2024 and aims to save the National Health Service (NHS) £14bn over five years.

Victoria Atkins MP takes over UK’s department of Health and Social Care

The UK government has seen a cabinet reshuffle as the Prime Minister removed Steve Barclay as UK health secretary and replaced him with newcomer, Victoria Atkins.

Telix strikes deal to distribute cancer imaging agent in the Nordics

The deal makes Danish Wiik Pharma the sole distributor of Telix’s prostate cancer imaging agent Illuccix across four European territories.

Trial sponsors say CROs need to own their mistakes and take responsibility

A panel discussion at a Copenhagen conference saw representatives from sponsor organisations sharing their hopes for CROs to take ownership when trials go wrong.

Sponsors urged to compensate oncology patients and meet trial staff face-to-face

Sponsors have been encouraged to keep their reputations above water and stave off bureaucratic slowdown to clinical trials by meeting clinicians face to face.

Voxzogo given green-light to treat children under five by US FDA

BioMarin has seen the label for its achondroplasia drug expand following two clinical trials that saw positive growth in children living with the condition.

Lipella gets go-ahead for trial studying chronic oral condition

The company has said that it is ready to launch a Phase IIa trial with the drug being intended to treat an often painful condition.

Five pharma firms fined €13.4m over EC’s cartel investigation

The European Commission has issued the firms with fines after they were found to have worked together to fix the sales of an antispasmodic drug.